Warning: count(): Parameter must be an array or an object that implements Countable in /home/customer/www/drugtrialsformoney.com/public_html/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 394

Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma

Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma
Conditions:   Merkel Cell Carcinoma;   Neuroendocrine Carcinoma of the Skin;   Trabecular Carcinoma of the Skin
Interventions:   Drug: Lenvatinib Oral Product;   Drug: Pembrolizumab
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Merck Sharp & Dohme Corp.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

May 4, 2021 / by / in
Comments